• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Aphena Pharma Solutions

    Almac Group

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    Emergent BioSolutions

    Adare Pharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharma Contract Manufacturing Pricing Analysis

    Expect increased prices over the next two years, but at slightly lower than historical trends

    Biopharma Contract Manufacturing Pricing Analysis
    Biopharma Contract Manufacturing Pricing Analysis
    Figure A: Past Two-Year Price Change (Source: HighTech Business Decisions)
    Biopharma Contract Manufacturing Pricing Analysis
    Figure B: Past Five-Year Price Change (Source: HighTech Business Decisions)
    Biopharma Contract Manufacturing Pricing Analysis
    Figure C: Expected Price Change (Source: HighTech Business Decisions)
    Biopharma Contract Manufacturing Pricing Analysis
    Figure D: Importance of Price by Project Type (Source: HighTech Business Decisions)
    William Downey, HighTech Business Decisions01.28.20
    Prices for biopharmaceutical contract manufacturing services continue to increase. Higher prices result from a better balance between supply and demand, higher overhead and labor expenses, and higher raw material costs. Both biopharmaceutical companies and contract manufacturing organizations see this upward price trend. These market participants expect increased prices over the next two years, but at rates slightly lower than historical trends.

    Background
    This article draws from HighTech Business Decisions’ latest report, “Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2019.” The analysis and conclusions in this report come from written surveys and interviews with executives at biopharmaceutical companies and contract manufacturing organizations. In this article, we define “biopharmaceuticals” as complex molecules created through the genetic manipulation of living cells or organisms used for therapeutics or vaccines. The terms “contractor” or “CMO” means organizations that produce biopharmaceuticals on a fee-for-service basis. This excludes organizations with only lab-scale production whose primary focus is development services.

    Past price changes
    Most biopharmaceutical respondents (“Users”) and CMOs report higher prices for contract manufacturing services over the past two years. Roughly one-fifth of the Users in our study report dramatically higher prices (greater than 10%), while six-tenths of the Users report price increases between 3% and 10%. Only one-fifth of the Users report stable or lower prices as seen in Figure A (note: all figures appear in the slider above). The CMOs report similar experiences. Slightly more than one-fifth of the CMOs note dramatically higher prices and more than seven-tenths of the CMOs report price increases greater than 3% over the past two years. Most respondents report increased prices for all outsourced services: 75% of the Users and 67% of the CMOs report across-the-board price increases.

    The respondents reporting across-the-board price increases point to higher overhead and labor expenses, the effects of higher demand, long lead times, and industry consolidation as the reasons for the price hikes. The other respondent group who reported higher prices for specific services listed higher prices for a) 1,000- to 2,500-L scale production, b) overall GMP production, c) analytical and development services, and d) plasmid production for immunotherapy and viral vectors. Below are selected respondent comments on price increases:
    • “There are general increases everywhere. I can’t unequivocally point my finger to specific drivers, but one thing that’s happening is that CMOs are acquiring more facilities and their cost structure is increasing. Users pay for that.”   —Pharmaceutical/Biotechnology Company
    • “Overall, there has been more business for process development and manufacturing. CMO’s capabilities and quality are good. Prices seem to be increasing across the board.”   —Pharmaceutical/Biotechnology Company
    • “The prices for plasmids for immunotherapy and viral vectors have changed the most due to the increase in demand. In 2018, we collected bids from five different CMOs and all of them had capacity. In 2019, three out of five of them were fully booked and too busy. For viral vectors, there is a six-month to a year backlog. Consumables may have increased around 3%.” —Pharmaceutical/ Biotechnology Company
    • “Pricing for our gene therapy and viral vaccine offerings have been changing the most. They are new technologies and we are getting a handle on where our place is in the market.” —Contract Manufacturer
    • “There has been a big demand increase and little capacity for microbiome production. Bacteria production as therapeutic has come back into fashion. In addition, we have seen an increase in microbial fermentation for the production of recombinant proteins.” —Contract Manufacturer

    Longer term price increases
    The recent price increases reported by all respondents are in line with the longer-term price trends reported by the CMOs. Over the past five years, prices charged by CMOs for manufacturing and related services have increased at an average rate of 5% a year. A few CMOs noted that annual price increases have varied, and that price changes for any given year may be higher or lower than their five-year trend. This long-term price trend is slightly higher than the annual producer price index of drugs and pharmaceuticals published by the U.S. Department of Labor, Bureau of Labor Statistics. Interestingly, the five-year price trend differs between CMO market segment. The CMOs that make commercial-phase products report lower than average annual price increases, and CMOs that only make noncommercial products report higher than average price increases. The commercial CMOs report a 4.7% average annual price increase, while the noncommercial CMOs report a 6.3% average annual price increase. The distribution of five-year price increases reported by the CMOs is shown in Figure B.

    One quantitative example of higher prices is the GMP batch price for mammalian cell culture production. From our studies, 37 prices were reported at the 500-L scale. The price sample includes both prices paid by Users and prices charged by CMOs. The average batch price in 2019 was $726±$149 thousand at the 90% confidence interval. This average price is 11% higher than the average batch price reported in our prior study. Also note, the batch price variation may result from the charges that CMOs either include or exclude in its batch price. Most CMOs include manufacturing time, quality assurance, and administrative costs in their batch price calculation. Conversely, CMOs typically exclude the cost of engineering runs, change orders, raw materials, and consumables from the batch price. There is no typical practice for other costs, such as, project management, research and development support, and quality control. 

    Future price changes
    In this study, we also asked the respondents about expected price changes for biopharmaceutical contract manufacturing services over the next two years. The respondents expect annual price increases of 3.7±0.6% at the 90% confidence interval. Most respondents expect annual price increases of 4%, while one-quarter of the respondents expect stable prices. The distribution of expected annual price increases is shown in Figure C. There is no significant difference of price expectations between the Users and CMOs. Also, most respondents expect across-the-board price increases, while a minority of respondents expect price increases for specific services. Those respondents who expect higher prices for specific services mention a) gene and cell therapies, b) 1,000- to 2,000-L batch production, and b) raw materials.

    Importance of price in CMO selection
    The Users also provided insights into the importance of price when choosing a CMO. Most Users rate price as either “most important” or “important” when choosing a CMO. However, the Users rate price as either a “neutral” or “not important” consideration for noncommercial projects.

    Overall, a slight majority of responses (53%) rate price as an important criterion for choosing a CMO. While price is an important consideration in the CMO decision, many Users note other important CMO attributes to consider. Some CMO attributes mentioned by the Users include a) track record, b) quality and quality systems, c) technical capability, d) technology, and e) capacity. Given the differences between CMOs and their service offerings, criteria other than price play an important role when choosing a CMO. 

    The importance of price significantly differs when choosing a CMO for either a commercial project or a noncommercial project. Users are more price sensitive for commercial projects. By a 3.4:1 ratio, Users consider price an important factor for commercial projects. Conversely, by a 0.4:1 ratio, Users consider price an important factor for noncommercial projects. Thus, Users are 8 times more likely to consider price an important factor in CMO choice for commercial projects compared with noncommercial projects. The chi-square test for independence shows this difference between commercial and noncommercial projects to be significant (Figure D). The p-value of 0.007 from the chi-square test allows us to reject the null hypothesis that price sensitivity is the same for each project type. This analysis shows Users are not equally price sensitive for commercial and noncommercial projects. 

    Below are selected comments from the respondents regarding the importance of price in CMO choice:
    • “Price is a lot more important as we move into commercial production. I would rank price closer to 1 when cost of goods matters.” —Pharmaceutical/Biotechnology Company 
    • “In preclinical projects, timing and speed are more important than price.” —Pharmaceutical/Biotechnology Company 
    • “Price would rank low. The parameters around compliance, quality, capacity, capability—i.e., the ability to be successful, get things done on time and not have issues with validation are much more important.” —Pharmaceutical/Biotechnology Company 
    • “For us, pricing is not generally important, nor critical, whereas quality and success are more important. With viral vectors, there are so few CMOs available that price negotiations are fruitless. It is a seller’s market. Therefore, if we don’t take the CMO’s offer, another company will quickly take our place, leaving us with no other option.” —Pharmaceutical/Biotechnology Company 
    • “It’s more important to meet timelines and be able to manufacture supply for clinical studies. Price is important and we look at it carefully, but it’s not our primary consideration. Most of our strategic partners understand that if they’re going to be opportunistic about it, then they’ll no longer be our strategic partner.” —Pharmaceutical/Biotechnology Company    
    • “Timeline and capacity are more important. Clinical supply is only one or two batches.” —Pharmaceutical/Biotechnology Company

    Closing
    Biopharmaceutical contract manufacturing prices have increased 5% a year over the past five years. Commercial project prices have increased at a slightly slower pace than noncommercial project prices. Prices will continue to increase over the next two years at 4% a year, slightly lower than the five-year trend. Prices are a bigger consideration when choosing a CMO for a commercial project compared to a noncommercial project. 


    William Downey is the president of HighTech Business Decisions, a market research and consulting company that has been publishing reports on the biopharmaceutical contract manufacturing market since 1997. For more information, visit www.hightechdecisions.com or call (408) 978-1035.
    Related Searches
    • it
    • Vaccine
    • vaccines
    • production

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20


    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20

    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20


    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Celonic Group Announces Plans For New Facility In Switzerland
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    First Source Worldwide, LLC Celebrates 20th Anniversary
    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Global Hair Color Market Forecasted to Grow
    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    Happi

    Latest Breaking News From Happi

    The Fragrance Foundation Celebrates Fragrance Day
    China To End Animal Testing for Imported 'Ordinary' Cosmetics
    Avon Launches Vegan Skin Care Line
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login